ライフサイエンスコーパス: neck cancer

1 (HNSCC) accounts for nearly 90% of head and neck cancer.

2 r cervical cancer and oropharyngeal head and neck cancer.

3 ard the betterment of patients with head and neck cancer.

4 dity and mortality in patients with head and neck cancer.

5 (HNSCC) is the most common form of head and neck cancer.

6 for viral mediated gene therapy of head and neck cancer.

7 effects associated with therapy for head and neck cancer.

8 data of 1,019 patients with lung or head-and-neck cancer.

9 phenotype existing in both lung and head-and-neck cancer.

10 (LR) and distant metastases (DM) in head-and-neck cancer.

11 hotosensitizer for PDT of resistant head and neck cancer.

12 tic relevance of targeting CXCR7 in head and neck cancer.

13 y or combined chemoradiotherapy for head and neck cancer.

14 r than lung, such as pancreatic and head and neck cancer.

15 ith lymphoma, colorectal cancer, or head and neck cancer.

16 st time high expression of CXCR7 in head and neck cancer.

17 e in patients with locally advanced head and neck cancer.

18 n tumor biopsies from patients with head and neck cancer.

19 this pathway as a strategy to treat head and neck cancer.

20 non-small-cell lung cancer, and in head and neck cancer.

21 plinary management of patients with head and neck cancer.

22 meats and sweets for prevention of head and neck cancer.

23 ccount for potency of E7 in causing head and neck cancer.

24 is the dominant HPV oncoprotein in head and neck cancer.

25 y resistance in HA-CD44v3-activated head and neck cancer.

26 uorouracil (PF) in locally advanced head and neck cancer.

27 ompared with PF in locally advanced head and neck cancer.

28 erapy for locally advanced squamous head and neck cancer.

29 rapy in patients with squamous cell head and neck cancer.

30 vely or negatively in patients with head and neck cancer.

31 nary management of various types of head and neck cancer.

32 ((18)F-FMISO) dynamic PET (dPET) in head and neck cancer.

33 nts with traditional, HPV-negative, head and neck cancer.

34 om neck dissection in patients with head and neck cancer.

35 apy resistance in HA/CD44-activated head and neck cancer.

36 tric cancer, urothelial cancer, and head and neck cancer.

37 rs constitute a unique entity among head and neck cancers.

38 ntion and treatment of HPV-positive head and neck cancers.

39 man cancers, including cervical and head-and-neck cancers.

40 ers, including cervical cancer, and head and neck cancers.

41 ple cancers, including cervical and head-and-neck cancers.

42 nt toxicity during radiotherapy for head and neck cancers.

43 esponse assessment using PET/CT for head and neck cancers.

44 vulvar, vaginal, penile, anal, and head-and-neck cancers.

45 d many other tumors, including many head and neck cancers.

46 he clinical workup of patients with head and neck cancers.

47 of lung (stage I), bladder, kidney, and head/neck cancers.

48 in patients with breast, lung, and head and neck cancers.

49 y associated with increased risk of head and neck cancers.

50 ing side effect of radiotherapy for head and neck cancers.

51 ncer, including cervical, anal, and head and neck cancers.

52 ovarian, cervical, bladder, lung, head, and neck cancers.

53 f cancer stem cells with a focus on head and neck cancers.

54 T for the treatment of non-melanoma head and neck cancers.

55 a prognostic marker for human oral/head and neck cancers.

56 lines and was co-expressed in human head and neck cancers.

57 t of acute hemorrhage from advanced head and neck cancers.

58 adenocarcinomas (PDA), prostate, or head and neck cancers.

59 ased risk of anogenital cancers and head and neck cancers.

60 mitant downregulation of rap1GAP in head and neck cancers.

61 H2), a histone methyltransferase in head and neck cancers.

62 on and poor prognosis in breast and head and neck cancers.

63 (HPV) cause certain anogenital and head and neck cancers.

64 in T-cell-inflamed tumor models of head and neck cancers.

65 as anticancer therapy for advanced head and neck cancers.

66 biomarkers for cervical as well as head and neck cancers.

67 alignancies, including cervical and head and neck cancers.

68 cinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenoc

69 ncer, 28.6 versus 35.5 versus 39.4; head and neck cancer, 21.1 versus 29.4 versus 40.2; and breast ca

70 o 46.4%), followed by patients with head and neck cancer (40.8%; 95% CI, 28.5% to 53.0%).

71 .5%), colorectal cancer (7.7%), and head and neck cancer (6.7%).

72 In head and neck cancer, a change in (18)F-FLT uptake early during r

73 ition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves re

74 HPV-negative head and neck cancers abundantly express EGFR, and the monoclonal

75 on-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically resistant t

76 e routinely obtained in the care of head and neck cancer and are clearly associated with patient outc

77 e routinely obtained in the care of head and neck cancer and are clearly associated with patient outc

78 ct together to efficiently suppress head and neck cancer and are, therefore, highly relevant targets

79 ty as well as invasive potential in head and neck cancer and breast cancer cells.

80 the early response to treatment of head and neck cancer and evaluated the association between PET pa

81 lid tumors including breast cancer, head and neck cancer and GIST.

82 stay of treatment for patients with head and neck cancer and has traditionally involved a stage-depen

83 reported the somatic alterations in head and neck cancer and have highlighted the distinct genetic an

84 Nude rats bearing human head and neck cancer and non-small cell lung cancer (NSCLC) xenog

85 s carrying BRCA mutations: one with head and neck cancer and one with ovarian cancer.

86 "oral clocks" and diseases such as head and neck cancer and Sjogren's syndrome.

87 essential role in the treatment of head and neck cancer and the care of patients and their families.

88 ese two genes, Ubiquitin C (UBC) in head and neck cancer and Transferrin receptor (TFRC) and beta-Glu

89 ts who had undergone irradiation of head and neck cancer and who had subsequent C1 or C2 lesions at M

90 d therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are

91 biology of recurrent and metastatic head and neck cancers and review implementation of precision onco

92 biology of recurrent and metastatic head and neck cancers and review implementation of precision onco

93 t in the diagnosis and treatment of head and neck cancer, and building surgical capacity, which offer

94 man cancers, including cervical and head and neck cancers, and is responsible for the annual deaths o

95 ng overweight before diagnosis with head and neck cancer are associated with a better prognosis.

96 View, several important studies in head and neck cancer are reviewed, with focus on issues raised by

97 Other HPV-associated anogenital and head and neck cancers are predicted to afflict another 700,000 me

98 pRb/p107-deficient mice developed head and neck cancer as frequently as do HPV-16 E7 transgenic mic

99 and pathogenesis of HPV-associated head-and-neck cancers as well as current treatment modalities for

100 es discussed in this Review include head and neck cancer, breast cancer, sarcoma, gastrointestinal ca

101 ets for therapeutic intervention in head and neck cancer but also may aid in the identification of po

102 can not only address the burden of head and neck cancer, but also create a platform for beginning to

103 s have elucidated relevant genes in head and neck cancer, but HPV-related tumors have consistently sh

104 eported in HPV-related cervical and head and neck cancers, but such data have not been available for

105 ing are considered risk factors for head and neck cancers, but the magnitude of effect estimates for

106 r APOBEC3B upregulation in cervical and head/neck cancers, but the mechanisms underlying nonviral mal

107 diation in resistant and aggressive head and neck cancer by 100-fold in vitro and 17-fold in vivo, re

108 o image unlabeled glucose uptake in head and neck cancer by using a clinical 3T magnetic resonance im

109 reatment for patients with advanced head and neck cancer can be associated with many side-effects, an

110 e conclude that glucoCEST images of head and neck cancer can be obtained with a clinical 3T MRI scann

111 Radiation therapy for head and neck cancer can result in extensive damage to normal adj

112 d with outcome when considering all head and neck cancer cases (HR for serology,0.49; 95% CI, 0.23-1.

113 sensitivity of the cisplatin-resistant head-neck cancer cell line Cal27CisR by almost 7-fold.

114 ovary cells and the UMSCC11B human head and neck cancer cell line protected EGFR from cisplatin-indu

115 We also show that head and neck cancer cell lines with loss-of-function mutations i

116 rrelated with cytotoxicity in seven head and neck cancer cell lines.

117 tinct between high and low invasive head and neck cancer cells and between CSCs and non-SCCs.

118 untargeted metabolomic analysis of head and neck cancer cells and stem-like cancer cells.

119 analysis of targeted metabolites in head and neck cancer cells as well as cancer stem-like cells (CSC

120 PNBs were generated in vivo in head and neck cancer cells by systemically targeting tumours with

121 versely, whereas p53 wild-type HN30 head and neck cancer cells did show sensitization to radiation up

122 the angiogenic chemokine CXCL1 from head and neck cancer cells in vitro, thus acting here as inverse

123 vidence that Hpa2 overexpression in head and neck cancer cells markedly reduces tumor growth.

124 we show that cisplatin treatment of head and neck cancer cells results in nuclear transport of p16 le

125 psilon led to increased survival of head and neck cancer cells under hypoxia, providing evidence that

126 protein kinase (AMPK) signaling in head and neck cancer cells.

127 s, but did not accelerate growth of head and neck cancer cells.

128 T) is a promising approach to treat head and neck cancer cells.

129 tion and increased death of ovarian and head/neck cancer cells.

130 motherapeutic resistance of ovarian and head/neck cancer cells.

131 med RNA-Seq of normoxic and hypoxic head and neck cancer cells.

132 le toxicity and biocompatibility in head and neck cancer cells.

133 al carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) in

134 el agents will hopefully streamline head and neck cancer chemoprevention research.

135 the incidence of tobacco-associated head and neck cancers decreased for elderly patients (larynx: APC

136 ors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alteration

137 of human cancer, but their role in head and neck cancer development and progression is not well defi

138 (HPV) sequences and that HPV-driven head and neck cancers display distinct biological and clinical fe

139 nimal studies in osteoarthritis and head and neck cancer, early blockade of NGF reduced weight loss i

140 found in subregions of cervical and head and neck cancers, enable HPV-positive cancer cells to escape

141 pooled data from the International Head and Neck Cancer Epidemiology (INHANCE) Consortium (comprisin

142 ,375 controls) in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium, we applie

143 Using data from the International Head and Neck Cancer Epidemiology Consortium, the authors conduct

144 aled that HPV-positive cervical and head-and-neck cancers exhibited higher rates of hA3 mutation sign

145 Head and neck cancer, for which the diagnosis and treatment are o

146 ,179 with kidney cancer, and 2,967 with head/neck cancer from five cohort studies.

147 accurate subtype identification in head and neck cancer from gene expression data in both formalin-f

148 th oropharyngeal cancer data from a head and neck cancer genome-wide association study (GWAS).

149 formation is available at: www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki .

150 nformation is available at www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki .

151 on, replicated significantly in the head and neck cancer GWAS limited to HPV-seropositive cases and a

152 hods to reduce SSI in patients with head and neck cancer have been intensely researched, yielding evo

153 interaction with the host genome in head and neck cancers have not been comprehensively described.

154 s of stage I lung, bladder, kidney, and head/neck cancers highlight the importance of smoking cessati

155 al HPV infection and HPV-associated head and neck cancer (HNC) among HIV-infected individuals.

156 of cancer, but prospective data on head and neck cancer (HNC) and oesophagus cancer are limited.

157 Patients with head and neck cancer (HNC) are at high risk of death resulting fr

158 tudies on smokeless tobacco use and head and neck cancer (HNC) have found inconsistent and often impr

159 Head and neck cancer (HNC) is the seventh most common cancer worl

160 Head and neck cancer (HNC) is the seventh most-common type of can

161 guidelines recommend patients with head and neck cancer (HNC) receive treatment at centers with expe

162 an papillomavirus (HPV+)-associated head and neck cancer (HNC) show significantly improved survival o

163 s on the management of adults after head and neck cancer (HNC) treatment, focusing on surveillance an

164 (EGFR) is an established target in head-and-neck cancer (HNC), resistance to EGFR-targeted therapy m

165 In patients with head and neck cancer (HNC), the surrounding normal salivary gland

166 er-associated fibroblasts (CAFs) in head and neck cancer (HNC), thereby promoting tumorigenesis via m

167 +) flux on TIL effector function in head and neck cancer (HNC).

168 g toxicity of chemoradiotherapy for head and neck cancer (HNC).

169 s is known about HPV integration in head and neck cancer (HNC).

170 and subsequent chemoradiotherapy of head and neck cancer (HNC).

171 s types of human cancers, including head and neck cancer (HNC).

172 Many cancer types, including head and neck cancers (HNC), express programmed death ligand 1 (P

173 ical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-stimulated

174 uction of oxidative stress in human head and neck cancer (HNSCC) cells.

175 body cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients,

176 etween use of smokeless tobacco and head and neck cancer in 11 US case-control studies.

177 nagement of locoregionally confined head and neck cancer in elderly patients and propose a practical

178 Head and neck cancer in elderly patients represents a major healt

179 e to the morbidity and mortality of head and neck cancer in India, Pakistan, and Bangladesh for 1 yea

180 ding the morbidity and mortality of head and neck cancer in India, Pakistan, and Bangladesh, along wi

181 In head and neck cancer in particular, proton beam therapy is unique

182 otal economic welfare losses due to head and neck cancer in the aforementioned countries in the year

183 n-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusetts, area (

184 n-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusetts, area (

185 ne derivatives for the treatment of head and neck cancer in the hamster cheek pouch oral cancer model

186 e of economic welfare losses due to head and neck cancer in the three studied countries is US$16.9 bi

187 rrelates with its ability to induce head and neck cancers in mice.

188 ndometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leuk

189 The current standard of care for head and neck cancer includes surgical resection of the tumor fol

190 immunological principles related to head and neck cancer, including the concept of cancer immunosurve

191 Among these cancers, HPV-associated head-and-neck cancers, inclusive of oropharyngeal squamous cell c

192 Odds ratios for head and neck cancer increase with greater cigarette and alcohol

193 close association in patients with head and neck cancer, indicating that the surrounding Treg cells

194 patients following radiotherapy for head and neck cancer is a common and significant problem, but the

195 Head and neck cancer is a leading cause of cancer-related mortali

196 Head and neck cancer is becoming more common, and survival rates

197 Head and neck cancer is one of the most prevalent cancers around

198 Head and neck cancer is the fifth most common cancer worldwide.

199 adiotherapy alone for patients with head and neck cancer is unclear.

200 e for predicting patient outcome in head and neck cancer is unknown.

201 and meet the needs of survivors of head and neck cancer is urgently required.

202 Recurrent and/or metastatic head and neck cancer is usually incurable.

203 rtance: Recurrent and/or metastatic head and neck cancer is usually incurable.

204 otherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR ge

205 ents with resected locally advanced head and neck cancer (LAHNC) with negative surgical margins (SM n

206 d trials in locoregionally advanced head and neck cancers (LAHNCs).

207 Epigenetic correlates of the head and neck cancer may illuminate its pathogenic roots.

208 dermal origins such as lung cancer, head and neck cancer, melanoma, and hepatocellular carcinoma.

209 to EGFR inhibition in HPV-negative head and neck cancer might help identify novel and active therapi

210 The heterotopic syngeneic murine head and neck cancer model (mEER) caused systemic inflammation an

211 have contributed to discovery of a head and neck cancer mutation association.

212 ith primary breast cancer (n = 13), head and neck cancer (n = 10), and lymphoma (n = 7) were evaluate

213 2 colorectal cancer (n = 96), and 4 head and neck cancer (n = 194).

214 ously administered to patients with head and neck cancer (n = 4) scheduled for surgery 5-7 d later.

215 l nervous system disorder (n = 51), head and neck cancer (n = 47), and other malignancy (n = 51).

216 reast (n = 7), stomach (n = 2), and head and neck cancers (n = 3), as well as unknown primary tumor (

217 though promising, for patients with head and neck cancer need to be demonstrated in prospective rando

218 a multivariable model, having lung/head and neck cancer (odds ratio [OR], 1.74; 95% CI, 1.26-2.41),

219 helonae infection in a patient with head and neck cancer on salvage chemotherapy, including the epide

220 are-as-usual (CAU) in patients with head and neck cancer or lung cancer who have psychological distre

221 ng distress levels of patients with head and neck cancer or lung cancer.

222 therapeutic radiation treatment for head and neck cancers or from the autoimmune disease Sjogren synd

223 tion of diet and weight status with head and neck cancer outcomes.

224 l carcinoma and a growing number of head-and-neck cancers, p53 is degraded by the viral oncoprotein E

225 haracteristics of acute and chronic head and neck cancer pain in humans.

226 use was positively associated with head and neck cancer, particularly for cancers of the oral cavity

227 nd their target mRNAs contribute to head and neck cancer pathogenesis and progression.

228 the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for phosphoryl

229 white women may be a new, emerging head and neck cancer patient population.

230 orrelates with enhanced survival of head and neck cancer patients (p < 0.0000542), indicating the imp

231 n of chemo-radiation treatments for head-and-neck cancer patients from different risk groups.

232 herapy is a promising treatment for head and neck cancer patients that suffer from chronic dry mouth

233 Head and neck cancer patients treated by radiation commonly suffe

234 a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy

235 preserve salivary gland function in head and neck cancer patients undergoing radiotherapy.

236 One hundred twenty head and neck cancer patients underwent 0- to 30-min (18)F-FMISO

237 salivary hypofunction in surviving head and neck cancer patients with Radiation Therapy Oncology Gro

238 In head and neck cancer patients, Hpa2 expression was markedly eleva

239 n independent data sets of lung and head-and-neck cancer patients, many of which were not identified

240 ating GRIM-19 mutations in a set of head and neck cancer patients.

241 bony metastases in heightened-risk head and neck cancer patients.

242 n response assessment in unselected head and neck cancer patients.

243 ssing supportive care issues facing head and neck cancer patients.

244 ility of multiparametric imaging in head and neck cancer patients.

245 l setting and in clinical trials in head and neck cancer patients.

246 fied 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx

247 Head and neck cancers positive for human papillomavirus (HPV) are

248 Head and neck cancers positive for human papillomavirus (HPV) hav

249 tal cancers and fentanyl family for head and neck cancers (PR, 1.39; 95% CI, 1.19 to 1.62) compared w

250 ied causative agent for a subset of head and neck cancers, primarily in the oropharynx, and is largel

251 d weight status are associated with head and neck cancer prognosis.

252 phosphorylation was associated with head and neck cancer progression, EGFR phosphorylation, and hepar

253 tumor suppressor axis to understand head and neck cancer progression.

254 rrelates with prostate, breast, and head and neck cancer recurrence.

255 idity and mortality associated with head and neck cancer remain high.

256 Recurrent/metastatic head and neck cancer remains a devastating disease with insuffici

257 Radiation therapy for head and neck cancer results in severe secondary side-effects in

258 Head and neck cancer risk was elevated for those who reported exc

259 HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera.

260 nly methylated and downregulated in head and neck cancers (SEPT9, SLC5A8, FUSSEL18, EBF3, and IRX1).

261 (SIR, 1.5), penile (SIR, 8.2), and head and neck cancer (SIR, 2.8), including subsites of head and n

262 mproved patient survival across all head and neck cancer sites: HR for oropharynx cancer, 0.26; 95% C

263 nnaire-Core 30 (QLQ-C30), the EORTC head and neck cancer-specific module (EORTC QLQ-H&N35), and the t

264 estingly, HPV-positive cervical and head-and-neck cancer specimens were recently shown to harbor sign

265 frequently reported in cervical and head and neck cancer specimens.

266 of collectively invading breast and head and neck cancer spheroids, here we identify hypoxia, a hallm

267 n vitro culture of undifferentiated head and neck cancer stem cells under low attachment conditions.

268 ed by sphere formation of colon and head and neck cancer stem cells under nonadherent conditions.

269 out functional interactions between head and neck cancer stem-like cells (CSC) and surrounding stroma

270 hich are distinct from HPV-negative head and neck cancers, suggesting that virus-associated tumors co

271 Head and neck cancer surgery is often a complex multi-step proced

272 As the population of head and neck cancer survivors increases, it has become increasin

273 te, breast, colorectal, esophageal, and head/neck cancers, the survival benefit associated with marri

274 Herein, we review late effects of head and neck cancer therapy, highlighting recent advances.

275 cohol consumption increase risk for head and neck cancers, there have been few attempts to model risk

276 portant role in chemosensitivity of head and neck cancers through ubiquitination of NFkappaB.

277 ossible biomarker of sensitivity of head and neck cancers to cell killing after PDT.

278 suggests that nurses can influence head and neck cancer treatment through emphasis on symptom manage

279 plications for our understanding of head and neck cancer tumorigenesis and for the use of targeted ag

280 cancer, cervical cancer, and HPV(+) head and neck cancer tumors.

281 ically activated proto-oncogenes in head and neck cancer tumors.

282 the molecular profiles of many rare head and neck cancer types are unknown.

283 Forty-eight patients with head and neck cancer underwent (18)F-FLT PET/CT before and during

284 -proven lymphoma, breast cancer, or head and neck cancer underwent (18)F-ISO-1 PET.

285 for primary staging or restaging of head and neck cancer underwent sequential whole-body (18)F-FDG PE

286 In clinical specimens of head and neck cancer, we found that coamplification of BMI1 and A

287 atments for patients with recurrent head and neck cancer, we reviewed the evidence on commonly used p

288 ed, non-metastatic, newly diagnosed head and neck cancer were eligible.

289 HPV-positive head and neck cancers were more heavily infiltrated by regulatory

290 ailure, acute myeloid leukemia, and head and neck cancers, whereas BS is characterized by growth reta

291 for colon, lung, hepatobiliary, and head and neck cancer, which are predominantly diseases of the eld

292 tic use from inhibiting Aurora A in head and neck cancers, which overexpress BMI1.

293 propriately selecting patients with head and neck cancer who can benefit from CTX in combination with

294 f 542 patients with newly diagnosed head and neck cancer who completed food-frequency questionnaires

295 tic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth

296 nonsquamous, squamous cell lung or head and neck cancers who were treated with the approved PD1-targ

297 r (SIR, 2.8), including subsites of head and neck cancer with confirmed HPV association (SIR for men,

298 We profiled a cohort of 279 head and neck cancers with next generation RNA and DNA sequencing

299 ng bony metastases in patients with head and neck cancers, with similar sensitivity to (18)F-FDG PET/

300 a patient-derived CXCR7-expressing head and neck cancer xenograft model in nude mice, tumor growth w